醋酸戈舍瑞林缓释植入剂与比卡鲁胺片联合前列腺癌根治术对高危前列腺癌患者的疗效分析

Efficacy of Goserelin Acetate Sustained-release Depot Combined with Radical Prostatectomy for Patients with High-risk Prostate Cancer

目的研究醋酸戈舍瑞林缓释植入剂与比卡鲁胺片联合前列腺癌根治术治疗高危前列腺癌的疗效。方法选取高危前列腺癌患者94例,随机分成观察组47例,对照组47例,两组患者均行前列腺癌根治术治疗,同时对照组加用比卡鲁胺片治疗,观察组加用醋酸戈舍瑞林缓释植入剂联合比卡鲁胺片治疗,比较两组患者的疗效、血清前列腺特异性抗原(PSA)、血清睾酮水平(T)、血清双氢睾酮水平(DHT)、血管内皮生长因子(VEGF)水平、血管内皮一氧化氮水平(NO)、尿道恢复情况(膀胱容积、尿流速率、残余尿量)、不良反应发生率。结果治疗后,观察组患者疗效较对照组好(P<0.05);治疗前,两组患者PSA、T、DHT、VEGF、NO水平比较无明显差异(P>0.05);治疗后,两组患者PSA、T、DHT、VEGF水平均降低,且观察组较对照组更低(P<0.05),两组患者NO水平均升高,且观察组较对照组更高(P<0.05);治疗后,观察组患者膀胱容积较对照组更小(P<0.05),观察组患者尿流速率较对照组更高(P<0.05),观察组患者残余尿量较对照组更少(P<0.05);两组患者不良反应发生率接近(P>0.05)。结论采用醋酸戈舍瑞林缓释植入剂、比卡鲁胺片联合前列腺癌根治术治疗高危前列腺癌患者可提高其疗效,同时降低血清PSA、VEGF水平,并改善患者尿控功能,安全性较高。

Objective To study the efficacy of goserelin acetate sustained-release depot and birucamide tablets combined with radical prostatectomy in the treatment of high-risk prostate cancer.Methods 94 patients with high-risk prostate cancer who were treated were selected as the study subjects and were randomly divided into the observation group(47 cases)and the control group(47 cases).Both groups of patients received radical prostatectomy,and the control group was additionally treated with bicalutamide tablets,and the observation group was additionally given goserelin acetate sustained-release depot combined with bicalutamide tablets.The efficacy,serum prostate specific antigen(PSA),serum testosterone(T),serum dihydrotestosterone(DHT),vascular endothelial growth factor(VEGF),vascular endothelial nitric oxide(NO),urethral recovery(bladder volume,urine flow rate,residual urine volume)and incidence rates of adverse reactions were compared between the 2 groups of patients.Results After treatment,the efficacy in the observation group was better than that in the control group(P<0.05).Before treatment,there were no significant differences in PSA,T,DHT,VEGF and NO between the 2 groups(P>0.05).After treatment,the levels of PSA,T,DHT,VEGF and NO were decreased in both groups,and the levels in the observation group were lower than those in the control group(P<0.05),and the level of NO was increased in both groups,and the level was higher in the observation group than that in the control group(P<0.05).After treatment,the bladder volume in the observation group was smaller than that in the control group(P<0.05),and the urine flow rate was higher than that in the control group(P<0.05),and the residual urine volume was less than that in the control group(P<0.05).The incidence rates of adverse reactions were close in both groups(P>0.05).Conclusion The application of goserelin acetate sustained-release depot and bicalutamide tablets combined with radical prostatectomy in the treatment of patients with high-risk prostate cancer can enhance the efficacy,reduce the levels of serum PSA and VEGF,and improve the urinary control function,with high safety.